Research programme: GPR40-GPR120 dual agonists - Advinus Therapeutics
Latest Information Update: 25 Jan 2016
At a glance
- Originator Advinus Therapeutics
- Mechanism of Action FFAR1 protein stimulants; GPR120 protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Research Type 2 diabetes mellitus
Most Recent Events
- 25 Jan 2016 Early research in Type-2 diabetes mellitus in India (unspecified route)
- 25 Jan 2016 GPR40-GPR120 dual agonists - Advinus Therapeutics is available for licensing as of 25 Jan 2016. www.advinus.com